Vaspin and its interacting molecules as therapeutic targets for metabolic syndrome

2016 Fiscal Year Final Research Report

• Project/Area Number: 26293218
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Partial Multi-year Fund
• Section: 一般
• Research Field: Metabolomics
• Research Institution: Okayama University
• Principal Investigator: Wada Jun 岡山大学, 医歯(薬)学総合研究科, 教授 (30294408)
• Research Collaborator: NAKATSUKA Atsuko 岡山大学病院, 腎臓・糖尿病・内分泌内科, 助教 (00625949)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Keywords: メタボリックシンドローム / アディポカイン / セリンプロテアーゼ / 小胞体ストレス / 肥満症

Outline of Final Research Achievements

We identified vaspin (visceral adipose tissue-derived serine protease inhibitor) as a novel adlipokine. Vaspin inhibits insulin resistance, fatty liver, dyslipidemia and atherosclerosis in metabolic syndrome. Vaspin inhibits kallikrein 7 belonging to serine protease and increases glucagon-like peptide-1. We generated DNAJC1 (DnaJ homolog, subfamily C, member 1) conditional knockout mice and we demonstrated that they are therapeutic targets for metabolic syndrome.

Free Research Field

内科学、糖尿病学、腎臓病学、肥満症、メタボリックシンドローム